These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2312764)

  • 1. Pharmacodynamic dependent disposition of the angiotensin converting enzyme inhibitor, libenzapril.
    Kochak GM; Choi RL; deSilva JK; Reydel-Bax P
    J Clin Pharmacol; 1990 Feb; 30(2):138-43. PubMed ID: 2312764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
    Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
    Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Ayala N; Caballero JMS; Muñoz A
    Res Vet Sci; 2017 Oct; 114():117-122. PubMed ID: 28371693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats.
    King JN; Maurer M; Toutain PL
    J Vet Pharmacol Ther; 2003 Jun; 26(3):213-24. PubMed ID: 12755906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of angiotensin-converting enzyme with libenzapril in normotensive males.
    Morgan JM; Piraino AJ; Saris SD; Graham CS; Hirschhorn WL; Kochak GM; Choi RL
    J Clin Pharmacol; 1994 Dec; 34(12):1177-82. PubMed ID: 7738213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN; Mauron C; Kaiser G
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum.
    Lecocq B; Funck-Brentano C; Lecocq V; Ferry A; Gardin ME; Devissaguet M; Jaillon P
    Clin Pharmacol Ther; 1990 Mar; 47(3):397-402. PubMed ID: 2311339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
    J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosinopril: pharmacokinetics and pharmacodynamics in Chinese subjects.
    Ding PY; Chu KM; Hu OY; Huang GM; Jeng JJ; Chang A; Delaney CL; MacAskill M; Yang BC; Jemal M; Smith R; Liao WC
    J Clin Pharmacol; 1999 Feb; 39(2):155-60. PubMed ID: 11563407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
    Martin NE; Collison KR; Martin LL; Tardif S; Wilding I; Wray H; Barrett JS
    J Clin Pharmacol; 2003 May; 43(5):529-38. PubMed ID: 12751274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.
    Stangier J; Su CA; Schöndorfer G; Roth W
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1355-64. PubMed ID: 11185634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of fosinopril in patients with various degrees of renal function.
    Hui KK; Duchin KL; Kripalani KJ; Chan D; Kramer PK; Yanagawa N
    Clin Pharmacol Ther; 1991 Apr; 49(4):457-67. PubMed ID: 1826651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach.
    Toutain PL; Lefebvre HP; King JN
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1087-93. PubMed ID: 10688627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers.
    De Lepeleire I; Van Hecken A; Verbesselt R; Kaiser G; Barner A; Holmes I; De Schepper PJ
    Eur J Clin Pharmacol; 1988; 34(5):465-8. PubMed ID: 3203706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of a new diacid angiotensin-converting enzyme inhibitor after intravenous administration of drug or prodrug to monkeys and dogs.
    Stuhler JD; Cheng H; Dorrbecker BR
    J Pharm Sci; 1992 Nov; 81(11):1071-3. PubMed ID: 1447706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril.
    Tang JP; Rakhit A; Douglas FL; Melethil S
    Pharm Res; 1992 Feb; 9(2):236-43. PubMed ID: 1553348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of food on the bioavailability of CGS 16617, an angiotensin-converting enzyme inhibitor, in healthy subjects.
    Choi RL; Kochak GM; Reydel-Bax P; Nelson EB
    J Clin Pharmacol; 1988 Sep; 28(9):848-52. PubMed ID: 3230152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of lisinopril.
    Beermann B
    Am J Med; 1988 Sep; 85(3B):25-30. PubMed ID: 2844083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of zofenopril calcium in healthy subjects.
    Singhvi SM; Foley JE; Willard DA; Morrison RA
    J Pharm Sci; 1990 Nov; 79(11):970-3. PubMed ID: 2292772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state.
    Parker E; Aarons L; Rowland M; Resplandy G
    Eur J Pharm Sci; 2005 Sep; 26(1):104-13. PubMed ID: 15982858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.